TABLE 2.

Pharmacokinetic-pharmacodynamic parameters of DQ-113, gatifloxacin, and ciprofloxacin in serum and lungs of mice infected with PRSP (n = 5)^a

Drug (MIC)	Dose (mg/kg)	Tissue	Cmax (μg/ml)	Tmax (h)	t1/2 (h)	AUC (mg · h/ml)	Lung/serum AUC ratio	AUC/MIC ratio
DQ-113 (0.004)	10	Serum	1.05	0.25	0.96	0.76	9.62	191.18
		Lung	3.82	0.5	1.19	7.31		1,826.94
GAFX (0.25)	10	Serum	2.00	0.25	0.58	1.71	3.24	6.82
		Lung	6.30	0.25	0.57	5.54		22.16
	50	Serum	10.39	0.25	0.93	15.13	2.76	60.54
		Lung	24.64	0.25	1.02	41.73		166.92
CPFX (0.5)	10	Serum	1.52	0.25	0.45	1.02	3.52	2.02
		Lung	3.44	0.25	0.57	3.59		7.19
	100	Serum	10.68	0.25	0.96	31.29	3.38	62.59
		Lung	35.37	1	1.19	105.87		211.75

^aAbbreviations: GAFX, gatifloxacin; CPFX, ciprofloxacin; C_max, maximum concentration of drug in serum; T_max, time to maximum concentration of drug in serum; t_1/2, half-life.